查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1970932

貪食症治療市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、通路、地區和競爭格局分類，2021-2031年

Binge eating Disorder Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球神經性貪食症治療市場預計將從 2025 年的 7.0815 億美元成長到 2031 年的 10.7532 億美元，複合年成長率為 7.21%。

該市場涵蓋一系列藥物療法和實證心理療法，旨在減少強迫性進食發作並治療相關的心理疾病。主要成長要素包括全球飲食障礙盛行率的上升以及由於意識提升而導致的診斷率增加。此外，中樞神經系統興奮劑的監管核准不斷擴大治療選擇。正如飲食障礙聯盟在2024年指出的那樣，神經性貪食症是美國成年人中最常見的飲食障礙，其患病人數是神經性厭食症和心因性暴食症總和的三倍。

市場概覽
預測期 2027-2031
市場規模：2025年 7.0815億美元
市場規模：2031年 1,075,320,000 美元
複合年成長率：2026-2031年 7.21%
成長最快的細分市場 抗憂鬱劑
最大的市場 北美洲

儘管有這些正面跡象，但由於專業治療費用高昂且醫療覆蓋範圍有限，患者在就醫方面仍面臨許多障礙。在精神衛生基礎設施資金不足的發展中地區，這種經濟負擔尤其沉重，導致潛在患者數量與實際獲得有效治療的患者數量之間存在巨大差距。因此，缺乏價格合理的治療方案可能會嚴重限制製造商的獲利能力，尤其是在對價格敏感的國際市場上。

市場促進因素

市場成長的主要驅動力是強大的臨床研發管線和藥物開發活動，其特點是研發方向正從傳統興奮劑轉向新型作用機制。製藥公司正積極推進後期臨床試驗，以緩解FDA核准治療方法的短缺，並在該領域投入大量資金。例如，Axsome Therapeutics在2024年4月的新聞稿中宣布啟動ENGAGE III期臨床試驗，以評估多巴胺-去甲腎上腺素再回收抑制劑souliamfetol對成人神經性貪食症患者的療效。這種臨床活動的成長也延伸至迷幻劑輔助療法等替代療法。 Tryptamine Therapeutics在2024年11月的臨床進展報告中宣布，其靜脈注射菇素製劑TRP-8803的Ib期臨床試驗已完成受試者給藥。

政府措施和優惠的報銷政策在改善市場准入和確立治療的醫療需求方面發揮著同等重要的作用。立法機構正日益加強撥款力度，以彌合診斷與有效治療之間的差距，尤其是在醫療服務體係不完善、早期發現至關重要的基層醫療機構。聯邦預算中用於培訓醫療服務提供者和改善基礎設施的資金也反映了這項努力。根據飲食飲食障礙聯盟於2024年4月發布的《2024會計年度資金方案》報告，該組織獲得了100萬美元的資金，用於為基層醫療服務提供者提供篩檢、簡短干預和治療轉診（SBIRT）方面的培訓。這些政策成果不僅有助於減少社會歧視，還能鼓勵醫療體系採用專門的暴食症（飲食障礙）治療方案，並為全球醫療服務提供者拓展商業性發展機會。

市場挑戰

高昂的專科治療費用和不足的保險報銷是全球神經性貪食症治療市場成長的主要障礙。這些經濟壁壘限制了患者獲得必要的藥物和心理治療，導致市場規模萎縮。當患者面臨過高的自付費用，且保險計劃缺乏對長期管理的全面保障時，高診斷率往往無法轉化為實際治療病例。這種缺口嚴重限制了製藥公司和醫療服務提供者的產生收入，尤其是在公共醫療資金不足以彌補資金缺口的地區。

這種經濟負擔規模龐大。根據蝴蝶基金會2024年的報告，澳洲飲食障礙造成的經濟和社會總成本估計為669億澳元，平均每人成本約為60,654澳元。如此高的個人成本凸顯了經濟危機，許多確診患者無力負擔持續治療費用。因此，這些經濟障礙阻礙了市場利用診斷趨勢的能力，抑制了已開發國家和對價格敏感的國際地區的成長。

市場趨勢

數位療法和行動醫療應用的融合正在從根本上改變市場格局，消除地理和物流方面的障礙，從而實現有效治療。虛擬優先的醫療模式獲得了廣泛的支持和投資者的信任，推動了遠距和可擴展干預措施的普及，這些措施是對傳統神經性貪食症治療的補充。這種數位化變革使醫療服務提供者能夠觸及服務不足的群體，並將循證治療直接送到患者家中，同時避免實體醫療機構人員配備的限制。作為這一趨勢的象徵，《行為健康商業》雜誌在2025年8月報道稱，虛擬醫療服務提供商Equip Health籌集了約4700萬美元的新股權融資，以滿足日益成長的、便捷的、技術輔助的遠距遠端醫療需求。

同時，專業治療中心市場正在進行策略整合，領先的行為健康醫療網路正在最佳化其業務組合，專注於臨床品質和營運效率。在這種競爭激烈的環境中，整合型營業單位優先考慮嚴格的資料收集，以證明治療效果，從而獲得支付方的報銷，並與分散的競爭對手區分開來。大型醫療機構正積極利用全網治療結果數據來檢驗住院和門診治療通訊協定的有效性。例如，根據 Odyssey Behavioral Healthcare 於 2025 年 10 月發布的《2024 年治療結果報告》，參與其飲食障礙住院計畫的成年患者的症狀總體減輕了 51%，這充分體現了此類專業整合系統所提供的臨床價值。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球暴食症治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按類型（抗憂鬱症、抗驚厥藥、興奮劑、其他）
    • 分銷通路（線下、線上）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美貪食症治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲神經性貪食症治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區貪食症治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東與非洲神經性貪食症治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲神經性貪食症治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球神經性貪食症治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Viatris Inc.
  • Johnson & Johnson Services, Inc.
  • Lupin Ltd.
  • Omeros Corp.
  • Pyramid Healthcare Inc.
  • Sumitomo Pharma Co. Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • Eli Lilly and Co
  • Tonix Pharmaceuticals Holding Corp.
  • Tryp Therapeutics Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 21708

The Global Binge Eating Disorder Treatment Market is projected to expand from USD 708.15 million in 2025 to USD 1075.32 million by 2031, reflecting a CAGR of 7.21%. This market encompasses a range of pharmacotherapeutic agents and evidence-based psychotherapies aimed at reducing compulsive overeating episodes and treating associated psychological conditions. Key growth drivers include the rising global prevalence of eating disorders and higher diagnosis rates resulting from enhanced mental health awareness. Additionally, regulatory approvals for central nervous system stimulants continue to widen therapeutic options. As noted by the Alliance for Eating Disorders in 2024, Binge Eating Disorder is the most prevalent eating disorder among U.S. adults, affecting three times as many individuals as Anorexia Nervosa and Bulimia Nervosa combined.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 708.15 MIllion
Market Size 2031USD 1075.32 MIllion
CAGR 2026-20317.21%
Fastest Growing SegmentAntidepressants
Largest MarketNorth America

Despite these positive indicators, the market confronts major obstacles due to the high costs associated with specialized treatment and insufficient insurance coverage, which limits patient access. This financial strain is particularly severe in developing regions where mental health infrastructure lacks adequate funding, creating a significant disparity between the number of potential patients and those receiving effective care. Consequently, the scarcity of affordable therapeutic alternatives could seriously restrict revenue potential for manufacturers, especially within price-sensitive international markets.

Market Driver

A primary engine for market growth is the robust clinical pipeline and drug development activity, marked by a transition toward novel mechanisms of action that go beyond traditional stimulants. Pharmaceutical firms are aggressively pushing late-stage trials to mitigate the shortage of FDA-approved therapies, drawing substantial investment into the sector. For instance, Axsome Therapeutics announced in a corporate press release in April 2024 the launch of the ENGAGE Phase 3 trial to assess solriamfetol, a dopamine and norepinephrine reuptake inhibitor, for treating adults with Binge Eating Disorder. This increase in clinical activity also encompasses alternative therapeutic classes, such as psychedelic-assisted treatments; Tryptamine Therapeutics reported in a November 2024 clinical update that it had completed subject dosing in a Phase 1b trial for TRP-8803, an IV-infused psilocin formulation.

Government initiatives and favorable reimbursement policies play an equally vital role in enhancing market accessibility and affirming the medical necessity of treatment. Legislators are increasingly designating funds to close the gap between diagnosis and effective care, particularly within underserved primary care environments where early detection is essential. This commitment is reflected in federal budgets aimed at improving provider training and infrastructure. According to an April 2024 report by the Eating Disorders Coalition regarding the Fiscal Year 2024 Funding Package, the organization secured $1 million specifically to train primary healthcare providers in screening, brief intervention, and referral to treatment (SBIRT). These policy achievements not only reduce stigma but also encourage healthcare systems to adopt specialized BED therapies, expanding the commercial reach for providers worldwide.

Market Challenge

The high expense of specialized care combined with insufficient insurance reimbursement represents a major hurdle to the growth of the Global Binge Eating Disorder Treatment Market. This economic barrier limits patient access to essential pharmacotherapeutic agents and psychotherapies, effectively shrinking the addressable market size. When patients encounter prohibitive out-of-pocket costs and insurance plans lack comprehensive coverage for long-term management, high diagnostic rates fail to convert into treated cases. This gap severely restricts revenue generation for pharmaceutical manufacturers and healthcare providers, particularly in areas where public health funding cannot cover the financial shortfall.

The scale of this financial burden is significant. As reported by the Butterfly Foundation in 2024, the total economic and social cost of eating disorders in Australia was estimated at $66.9 billion, with per-person costs averaging approximately $60,654. Such high individual expenses underscore an affordability crisis that precludes a large portion of the diagnosed population from obtaining consistent care. As a result, these financial obstacles hinder the market's capacity to leverage rising diagnostic trends, thereby stalling growth in both developed nations and price-sensitive international regions.

Market Trends

The integration of digital therapeutics and mobile health applications is fundamentally transforming the market by removing geographical and logistical obstacles to effective care. Virtual-first care models are securing significant traction and investor confidence, supporting a shift toward remote, scalable interventions that augment traditional Binge Eating Disorder therapy. This digital evolution enables providers to access underserved populations and administer evidence-based treatments directly to patients' homes, circumventing the capacity limits of physical facilities. Highlighting this trend, Behavioral Health Business reported in August 2025 that virtual provider Equip Health raised nearly $47 million in new equity funding to meet the growing demand for accessible, technology-enabled remote care.

Simultaneously, the market is experiencing a strategic consolidation of specialized treatment centers as major behavioral health networks refine their portfolios to focus on clinical quality and operational efficiency. In this competitive environment, consolidated entities are emphasizing rigorous data collection to prove treatment efficacy, thereby securing payer reimbursement and distinguishing their care models from fragmented competitors. Large-scale providers are increasingly utilizing network-wide outcome data to validate their residential and outpatient protocols. For example, Odyssey Behavioral Healthcare's October 2025 '2024 Treatment Outcomes Report' indicated that adults in their residential eating disorder programs achieved a 51% overall reduction in symptoms, demonstrating the clinical value delivered by these specialized, consolidated systems.

Key Market Players

  • Viatris Inc.
  • Johnson & Johnson Services, Inc.
  • Lupin Ltd.
  • Omeros Corp.
  • Pyramid Healthcare Inc.
  • Sumitomo Pharma Co. Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • Eli Lilly and Co
  • Tonix Pharmaceuticals Holding Corp.
  • Tryp Therapeutics Inc

Report Scope

In this report, the Global Binge eating Disorder Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Binge eating Disorder Treatment Market, By Type

  • Antidepressants
  • Anticonvulsants
  • Stimulants
  • Others

Binge eating Disorder Treatment Market, By Distribution Channel

  • Offline
  • Online

Binge eating Disorder Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Binge eating Disorder Treatment Market.

Available Customizations:

Global Binge eating Disorder Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Binge eating Disorder Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Antidepressants, Anticonvulsants, Stimulants, Others)
    • 5.2.2. By Distribution Channel (Offline, Online)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Binge eating Disorder Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Binge eating Disorder Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Binge eating Disorder Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Binge eating Disorder Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Distribution Channel

7. Europe Binge eating Disorder Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Binge eating Disorder Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. France Binge eating Disorder Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Binge eating Disorder Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Binge eating Disorder Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Binge eating Disorder Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Binge eating Disorder Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Binge eating Disorder Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Binge eating Disorder Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Binge eating Disorder Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Binge eating Disorder Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Binge eating Disorder Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Binge eating Disorder Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Binge eating Disorder Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. UAE Binge eating Disorder Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. South Africa Binge eating Disorder Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Distribution Channel

10. South America Binge eating Disorder Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Binge eating Disorder Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Colombia Binge eating Disorder Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Argentina Binge eating Disorder Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Binge eating Disorder Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Viatris Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Johnson & Johnson Services, Inc.
  • 15.3. Lupin Ltd.
  • 15.4. Omeros Corp.
  • 15.5. Pyramid Healthcare Inc.
  • 15.6. Sumitomo Pharma Co. Ltd.
  • 15.7. Takeda Pharmaceutical Co. Ltd.
  • 15.8. Eli Lilly and Co
  • 15.9. Tonix Pharmaceuticals Holding Corp.
  • 15.10. Tryp Therapeutics Inc

16. Strategic Recommendations

17. About Us & Disclaimer